BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
05 February 2019 - 11:00PM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company will present an abstract including results from the
ZENITH-1 study at the upcoming annual meeting of the American
Academy of Allergy, Asthma & Immunology (AAAAI) February 22-25
in San Francisco.
- Oral Plasma Kallikrein Inhibitor
BCX7353 is Safe and Effective as an On-Demand Treatment of
Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results
of the ZENITH-1 Trial; Session 2209, Urticaria and Angioedema,
Poster 110, Moscone Center South, Exhibition Level, Hall B,
Saturday, February 23, 9:45 a.m. PT
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. BioCryst has several ongoing
development programs including BCX7353, an oral treatment for
hereditary angioedema, galidesivir, a potential treatment for
Marburg virus disease and Yellow Fever, and a preclinical program
to develop oral ALK-2 inhibitors for the treatment of
fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir
injection), a viral neuraminidase inhibitor for the treatment of
influenza, is BioCryst's first approved product and has received
regulatory approval in the U.S., Canada, Australia, Japan, Taiwan,
Korea and the European Union. Post-marketing commitments for
RAPIVAB are ongoing. For more information, please visit the
Company's website at www.BioCryst.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: that ongoing and future preclinical and
clinical development of HAE second generation drug candidates
(including ZENITH-1, APeX-2, APeX-S and APeX-J) may not have
positive results, may be more expensive or may not move as quickly
as planned; that the FDA, EMA or other applicable regulatory agency
may not provide regulatory clearances which may result in delay of
planned clinical trials or failure to achieve market approval for
product candidates. Please refer to the documents BioCryst files
periodically with the Securities and Exchange Commission,
specifically BioCryst’s most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
all of which identify important factors that could cause the actual
results to differ materially from those contained in BioCryst’s
projections and forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2024 to May 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From May 2023 to May 2024